Evolving Treatment Landscape for Relapsed/Refractory Multiple Myeloma

Ryan Haumschild, PharmD, MS, MBA, leads a discussion surrounding relapsed/refractory multiple myeloma (MM).

Ryan Haumschild, PharmD, MS, MBA, leads a panel surrounding individualized strategies for treating patients with relapse/refractory (RR) MM.

A panel of experts explore burdens facing patients diagnosed with RRMM.

Kathryn Maples, PharmD, BCOP, provides insights regarding unmet needs in treatment for relapsed/refractory multiple myeloma.

A panel of experts navigate the treatment landscape in multiple myeloma.

Medical experts emphasize anti-CD38 agent utilization for treatment of patients with multiple myeloma.

Dr Haumschild leads a discussion surrounding key considerations when using anti-CD38 drugs.

Experts discuss the results of the IKEMA and CANDOR trials.

4-drug treatment regimens could provide optimal care strategies for patients with multiple myeloma.

Key opinion leaders emphasize the critical role of effective clinical pathways for treatment in multiple myeloma.

Total cost of care for multiple myeloma can be significantly affected by selection of dosing regimen.

Toxicity management associated with anti-CD38 drugs is highlighted by a panel of medical experts.

In their closing thoughts, Mr Haumschild leads the panel in a discussion regarding treatments on the horizon for patients with relapsed/refractory multiple myeloma.